

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 31937

Title: Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma

Reviewer's code: 02445450

Reviewer's country: United States

Science editor: Fang-Fang Ji

Date sent for review: 2016-12-19

Date reviewed: 2017-01-01

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The diagnosis of PDCA is challenging, but diagnosis of PDCA using pancreatic juice is worth further investigation. It is already known, but not decisive, to use k-ras, p53 mutation, DNA methylation, telomerase mutation, mitochondrial DNA mutation, and miRNAs in pancreatic juice for estimation of existence of PDCA. Please explain why CA19-9, CEA, and LDH are chosen as biomarkers to be used, while other promising markers are known. Also, if sensitivity and specificity are shown in combination of CA19-9, CEA, and LDH, that would be very helpful.

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 31937

Title: Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma

Reviewer's code: 03397121

Reviewer's country: Germany

Science editor: Fang-Fang Ji

Date sent for review: 2017-03-09

Date reviewed: 2017-03-11

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The manuscript by Shefali Agrawal reviews potential biomarkers in pancreatic juice and bile for pancreatic ductal adenocarcinoma. This is a well written, concise and up-to-date review of the topic. The relevant literature is cited and discussed. A graph or table with the potential biomarkers would be helpful as well as the level of evidence for the most promising markers.

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 31937

Title: Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma

Reviewer's code: 00183279

Reviewer's country: India

Science editor: Fang-Fang Ji

Date sent for review: 2017-03-10

Date reviewed: 2017-03-20

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The article is well written and gives a good insight about prognostic markers in bile and pancreatic juice of resectable pancreatic ductal adenocarcinoma patients. 1. Level of markers (cut off value) in body fluid needs to be mentioned. 2. The relation of those markers and the level of preoperative hyperbilirubin levels needs to be mentioned. 3. The level of markers and relation with stage of primary disease needs to be incorporated. 4. A good study, however, a further research on body fluid biomarkers for identification of early disease and selection of patients for further treatment may be proposed.